A Phase 1, Multicenter, Open-Label, Single-Arm, Multiple Dose Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Natalizumab in Pediatric Subjects with Relapsing Remitting Multiple Sclerosis

Registry ID

EUCTR2012-005082-13

Source registry

EUCTR

Status

Completed

Phase

PHASE1

Sponsor

Biogen Idec Research Limited

Start date

2013-04-02

Last update

2026-08-16

Conditions

• Relapsing Remitting Multiple Sclerosis

Summary

The primary objective of the study is to determine the PK profile of multiple doses of natalizumab in pediatric subjects with RRMS.

Locations

• , , Italy

Related clinical trials

• A Phase 3, Multicenter, Double Blind, Active-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral Ozanimod Compared to Oral Fingolimod in Children and Adolescents with Relapsing Remitting Multiple Sclerosis
• The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study
• Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
• SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis
• Visual Processing Speed and Objective Analysis of Ocular Movements in Multiple Sclerosis
• Rituximab and Ocrelizumab in Serum With Multiple Sclerosis

View on source registry